Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_3_suppst3.pdf
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
Le X et al.
Jco Precision Oncology, 2021
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M et al.
Oncotarget, 2015
NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.
Shin JS et al.
Investigational New Drugs, 2014
Select a paper to view details